The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;
In 2022, the states with the highest number of HIV diagnoses were Texas, California, and Florida. That year, there were a total of around 37,601 HIV diagnoses in the United States. Of these, 4,896 were diagnosed in Texas. HIV infections have been decreasing globally for many years. In the year 2000, there were 2.8 million new infections worldwide, but this number had decreased to around 1.3 million new infections by 2023. The number of people living with HIV remains fairly steady, but the number of those that have died due to AIDS has reached some of its lowest peaks in a decade. Currently, there is no functional cure for HIV or AIDS, but improvements in therapies and treatments have enabled those living with HIV to have a much improved quality of life.
This dataset contains surveillance data on diagnoses of HIV for the United States in estimates rates and numbers for Human Immunodeficiency Virus (HIV) infection diagnosis and stage 3 infection Acquired Immunodeficiency Syndrome (AIDS) as collected by the Centers for Disease Control and Prevention (CDC).
In 2022, Black or African Americans had the highest rates of HIV diagnoses among males in the United States. In that year, among all men, 22 per 100,000 men were diagnosed with HIV. This statistic displays the rate of HIV diagnoses among males in the U.S. in 2022, by race and ethnicity (per 100,000 population).
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Prevalence of HIV, total (% of population ages 15-49) in United States was reported at 0.4 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Prevalence of HIV, total (% of population ages 15-49) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.
In 2022, the estimated number of HIV diagnoses in the Midwest stood at 4,903. This statistic shows the number of HIV (human immunodeficiency virus) diagnoses in the United States from 2018 to 2022, by region of residence.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2019. This stayed constant from the previous number of 0.110 Ratio for 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 0.130 Ratio in 2012 and a record low of 0.110 Ratio in 2019. United States US: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].
MIT Licensehttps://opensource.org/licenses/MIT
License information was derived automatically
Rates of HIV diagnoses among adults and adolescents ages 13 and older in the US by state, 2016. Source: Centers for Disease Control and Prevention (CDC), Diagnoses of HIV infection in the United States and dependent areas, 2016. HIV surveillance report, 2017; vol 28.
The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).
In 2022, Black or African Americans accounted for 50 percent of all HIV diagnoses among females in the United States. This statistic shows the distribution of HIV diagnoses among females in the U.S. in 2022, by race and ethnicity.
In 2022, the estimated number of HIV diagnoses for males aged 13 years and over was 30,935. This statistic shows the estimated number of HIV (human immunodeficiency virus) diagnoses in the U.S. from 2018 to 2022, by sex assigned at birth and age.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
aIncludes cases of HIV infection, newly diagnosed in Australia in 2010 and reported by 31 March 2012. The exposure category “Heterosexual contact” includes cases from high prevalence countries in sub-Saharan Africa and specific countries in South East Asia (Burma, Cambodia).bDataset is not nationally representative; it includes data from 5 of the 13 provinces and territories. Across all 13 provinces and territories, a total of 2,358 HIV cases were reported in 2010. The case definition for AIDS in Canada is based on confirmed HIV diagnosis and presence/diagnosis of an AIDS-defining condition (no criteria for CD4 count are included in Canada’s AIDS case definition).cData for the whole country, adjusted for under-reporting and reporting delays. Missing data on age,sex, transmission category and clinical stage are imputed. Data reported as of 30 June, 2011. MSM-IDU are in “others”.dIn 2010 the coverage of HIV surveillance system is 97.8%. AIDS is undereported. AIDS defined as clinical stage C (CDC classification).eIncludes cases of HIV infection, newly diagnosed in the United States in 2010 and reported by 31 December 2011. Estimated numbers resulted from statistical adjustment that accounted for missing risk-factor information, but not for reporting delays and incomplete reporting.fMSM, men who have sex with men; IDU, injection drug use.
The Find Ryan White HIV/AIDS Medical Care Providers tool is a locator that helps people living with HIV/AIDS access medical care and related services. Users can search for Ryan White-funded medical care providers near a specific complete address, city and state, state and county, or ZIP code. Search results are sorted by distance away and include the Ryan White HIV/AIDS facility name, address, approximate distance from the search point, telephone number, website address, and a link for driving directions. HRSA's Ryan White program funds an array of grants at the state and local levels in areas where most needed. These grants provide medical and support services to more than a half million people who otherwise would be unable to afford care.
The HIV Testing Sites & Care Services Locator is a first-of-its-kind, location-based search tool that allows you to search for testing services, housing providers, health centers and other service providers near your current location.
The 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS) is a cross-sectional survey that will assess the prevalence of key human immunodeficiency virus (HIV)-related health indicators. This survey is a two-stage cluster survey of 88,775 randomly-selected households in Nigeria, sampled from among 3,551 nationally-representative sample clusters. The survey is expected to include approximately 168,029 participants, ages 15-64 years and children, ages 0-14 years, from the selected household. The 2018 NAIIS will characterize HIV incidence, prevalence, viral load suppression, CD4 T-cell distribution, and risk behaviors in a household-based, nationally-representative sample of the population of Nigeria, and will describe uptake of key HIV prevention, care, and treatment services. The 2018 NAIIS will also estimate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV) infections, and HBV/HIV and HCV/HIV co-infections.
National coverage, the survey covered the Federal Republic and was undertaken in each state and the Federal Capital.
Household Health Survey
Sample survey data [ssd]
This cross-sectional, household-based survey uses a two-stage cluster sampling design (enumeration area followed by households). The target population is people 15-64 and children ages 0-14 years. The overall size and distribution of the sample is determined by analysis of existing estimates of national HIV incidence, sub-national HIV prevalence, and the number of HIV-positive cases needed to obtain estimates of VLS among adults 15-64 years for each of the 36 states and the FCT while not unnecessarily inflating the sample size needed.
From a sampling perspective, the three primary objectives of this proposal are based on competing demands, one focused on national incidence and the other on state-level estimates in a large number of states (37). Since the denominator used for estimating VLS is HIV-positive individuals, the required minimum number of blood draws in a stratum is inversely proportional to the expected HIV prevalence rate in that stratum. This objective requires a disproportionate amount of sample to be allocated to states with the lowest prevalence. A review of state-level prevalence estimates for sources in the last 3 to 5 years shows that state-level estimates are often divergent from one source to the next, making it difficult to ascertain the sample size needed to obtain the roughly 100 PLHIV needed to achieve a 95% confidence interval (CI) of +/- 10 for VLS estimates.
An equal-size approach is proposed with a sample size of 3,700 blood specimens in each state. Three-thousand seven hundred specimens will be sufficiently large to obtain robust estimates of HIV prevalence and VLS among HIV-infected individuals in most states. In states with a HIV prevalence above 2.5%, we can anticipate 95% CI of less than +/-10% and relative standard errors (RSEs) of less than 11% for estimates of VLS. In these states, with HIV prevalence above 2.5%, the anticipated 95% CI around prevalence is +/- 0.7% to a high of 1.1-1.3% in states with prevalence above 6%. In states with prevalence between 1.2 and 2.5% HIV prevalence estimates would remain robust with 95% CI of +/- 0.5-0.6% and RSE of less than 20% while 95% CI around VLS would range between 10-15% (and RSE below 15%). With this proposal only a few states, with HIV prevalence below 1.0%, would have less than robust estimates for VLS and HIV prevalence.
Face-to-face [f2f]
Three questionnaires were used for the 2018 NAIIS: Household Questionnaire, Adult Questionnaire, and Early Adolescent Questionnaire (10-14 Years).
During the household data collection, questionnaire and laboratory data were transmitted between tablets via Bluetooth connection. This facilitated synchronization of household rosters and ensured data collection for each participant followed the correct pathway. All field data collected in CSPro and the Laboratory Data Management System (LDMS) were transmitted to a central server using File Transfer Protocol Secure (FTPS) over a 4G or 3G telecommunication provider at least once a day. Questionnaire data cleaning was conducted using CSPro and SAS 9.4 (SAS Institute Inc., Cary, North Carolina, United States). Laboratory data were cleaned and merged with the final questionnaire database using unique specimen barcodes and study identification numbers.
A total of 101,267 households were selected, 89,345 were occupied and 83,909 completed the household interview . • For adults aged 15-64 years, interview response rate was 91.6% for women and 88.2% for men; blood draw response rate was 92.9% for women and 93.6% for men. • For adolescents aged 10-14 years, interview response rate was 86.8% for women and 86.2% for men; blood draw response rate was 91.2% for women and 92.3% for men. • For children aged 0-9 years, blood draw response rate was 68.5% for women and men.
Estimates from sample surveys are affected by two types of errors: non-sampling errors and sampling errors. Non-sampling errors result from mistakes made during data collection, e.g., misinterpretation of an HIV test result and data management errors such as transcription errors during data entry. While NAIIS implemented numerous quality assurance and control measures to minimize non-sampling errors, these were impossible to avoid and difficult to evaluate statistically. In contrast, sampling errors can be evaluated statistically. Sampling errors are a measure of the variability between all possible samples.
The sample of respondents selected for NAIIS was only one of many samples that could have been selected from the same population, using the same design and expected size. Each of these samples could yield results that differed somewhat from the results of the actual sample selected. Although the degree of variability cannot be known exactly, it can be estimated from the survey results. The standard error, which is the square root of the variance, is the usual measurement of sampling error for a statistic (e.g., proportion, mean, rate, count). In turn, the standard error can be used to calculate confidence intervals within which the true value for the population can reasonably be assumed to fall. For example, for any given statistic calculated from a sample survey, the value of that statistic will fall within a range of approximately plus or minus two times the standard error of that statistic in 95% of all possible samples of identical size and design.
NAIIS utilized a multi-stage stratified sample design, which required complex calculations to obtain sampling errors. The Taylor linearization method of variance estimation was used for survey estimates that are proportions, e.g., HIV prevalence. The Jackknife repeated replication method was used for variance estimation of more complex statistics such as rates, e.g., annual HIV incidence and counts such as the number of people living with HIV.
The Taylor linearization method treats any percentage or average as a ratio estimate, , where y represents the total sample value for variable y and x represents the total number of cases in the group or subgroup under consideration. The variance of r is computed using the formula given below, with the standard error being the square root of the variance: in which Where represents the stratum, which varies from 1 to H, is the total number of clusters selected in the hth stratum, is the sum of the weighted values of variable y in the ith cluster in the hth stratum, is the sum of the weighted number of cases in the ith cluster in the hth stratum and, f is the overall sampling fraction, which is so small that it is ignored.
In addition to the standard error, the design effect for each estimate is also calculated. The design effect is defined as the ratio of the standard error using the given sample design to the standard error that would result if a simple random sample had been used. A design effect of 1.0 indicates that the sample design is as efficient as a simple random sample, while a value greater than 1.0 indicates the increase in the sampling error due to the use of a more complex and less statistically efficient design. Confidence limits for the estimates, which are calculated as where t(0.975, K) is the 97.5th percentile of a t-distribution with K degrees of freedom, are also computed.
Remote data quality check was carried out using data editor
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
AimsTwo behavioral HIV prevention interventions for people who inject drugs (PWID) infected with HIV include the Holistic Health Recovery Program for HIV+ (HHRP+), a comprehensive evidence-based CDC-supported program, and an abbreviated Holistic Health for HIV (3H+) Program, an adapted HHRP+ version in treatment settings. We compared the projected health benefits and cost-effectiveness of both programs, in addition to opioid substitution therapy (OST), to the status quo in the U.S.MethodsA dynamic HIV transmission model calibrated to epidemic data of current US populations was created. Projected outcomes include future HIV incidence, HIV prevalence, and quality-adjusted life years (QALYs) gained under alternative strategies. Total medical costs were estimated to compare the cost-effectiveness of each strategy.ResultsOver 10 years, expanding HHRP+ access to 80% of PWID could avert up to 29,000 HIV infections, or 6% of the projected total, at a cost of $7,777/QALY gained. Alternatively, 3H+ could avert 19,000 infections, but is slightly more cost-effective ($7,707/QALY), and remains so under widely varying effectiveness and cost assumptions. Nearly two-thirds of infections averted with either program are among non-PWIDs, due to reduced sexual transmission from PWID to their partners. Expanding these programs with broader OST coverage could avert up to 74,000 HIV infections over 10 years and reduce HIV prevalence from 16.5% to 14.1%, but is substantially more expensive than HHRP+ or 3H+ alone.ConclusionsBoth behavioral interventions were effective and cost-effective at reducing HIV incidence among both PWID and the general adult population; however, 3H+, the economical HHRP+ version, was slightly more cost-effective than HHRP+.
The Housing Opportunities for Persons with AIDS (HOPWA) program funds are distributed to states and cities by formula allocations and made available as part of the area's Consolidated Plan. Persons living with HIV/AIDS and their families may require housing that provides emergency, transitional, or long-term affordable solutions. In addition, some projects are selected in national competitions to serve as service delivery models or operate in non-formula areas. Grantees partner with nonprofit organizations and housing agencies to provide housing and support to beneficiaries.
To learn more about the HOPWA program visit: https://portal.hud.gov/hudportal/HUD?src=/program_offices/comm_planning/aidshousing, for questions about the spatial attribution of this dataset, please reach out to us at GISHelpdesk@hud.gov. Data Dictionary: DD_HOPWA Grantee Areas
Date of Coverage: FY 2024 Data Updated: Annually
In 2022, the death rate from HIV was highest among African Americans, with around 19 deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2022, by race and ethnicity, per 100,000 population.
The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.